Case at a Glance
Acting on an anonymous complaint that AbbVie Healthcare India had funded “pleasure trips” for 30 healthcare professionals to conferences in Paris and Monaco in 2024, the Department of Pharmaceuticals ordered a special audit, and the Apex Committee for Pharma Marketing Practices reprimanded the company and asked the CBDT and NMC to act, although the industry body’s Ethics Committee had found no irregularity. The Karnataka High Court held that the anonymous nature of the complaint was no ground to quash the order, that the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024 governed the DOP’s procedure, and that the Ethics Committee’s decision did not bind the DOP. It dismissed the writ petition, allowing the Income Tax Department and the Registrar of Companies to proceed, with the ROC directed to strictly follow Section 206(4) of the Companies Act.
The Department of Pharmaceuticals received an anonymous complaint on 21 May 2024 alleging that AbbVie had funded trips for 30 healthcare professionals to IMCAS 2024 (Paris, 1 to 3 February 2024) and AMWC 2024 (Monaco, 26 to 29 March 2024) under the guise of conferences. The Ethics Committee for Pharma Marketing Practices of the industry association (OPPI) found no irregularity, reasoning that UCPMP 2014 governed and that an anonymous complaint could not be entertained. Separately, the DOP ordered a special audit on 2 September 2024.
On 23 December 2024 the Apex Committee for Pharma Marketing Practices passed an order reprimanding the company “for unethical marketing practices” and requesting the CBDT and the National Medical Commission to take action. Income Tax summonses followed in January and February 2026, and the Registrar of Companies issued a notice on 12 May 2026. AbbVie challenged the Apex Committee order and the consequential proceedings.
The Key Question Before the Court
Could the Apex Committee act on an anonymous complaint and on the DOP’s own inquiry despite the Ethics Committee’s contrary decision, without any appeal or review, and should the consequential Income Tax and ROC proceedings be quashed?
The DOP’s Independent Channel Under UCPMP 2024
Justice Suraj Govindaraj held that “the anonymous nature of the complaint is not a ground for quashing the impugned order.” Clauses 10.3 and 10.4 of UCPMP 2024 apply to complaints lodged with an association’s Ethics Committee; “Those provisions, however, do not bar the DOP from receiving a complaint” and verifying it through a special audit under Clause 10.7. Since “UCPMP 2024 governed the procedure followed by the DOP when it received the complaint on 21.05.2024”, the Court did not need to rely on UCPMP 2014. On the Ethics Committee’s clean chit, it held that the decision was “final within the Association’s complaint mechanism but did not bind the DOP”; the Apex Committee “did not sit in appeal over or set aside the ECPMP’s decision”, so “the absence of an appeal or review under Clause 13 does not invalidate the impugned order.” The special audit was not vitiated because auditors were not drawn from a panel under Clause 14.3.
On the consequential proceedings, the Court held that the ROC’s power flows from Section 206 of the Companies Act and it “does not require a direction from the Apex Committee”; but “The impugned order cannot be treated as a final finding binding on the ROC”, which must give written allegations, specify the matters and allow a hearing, applying Union of India v. Ram Lakhan Sharma, (2018) 07 SC CK 0001 and Union of India v. Mahendra Singh on fairness and strict procedure. The Income Tax summonses were not shown to be issued solely because of the impugned order, and the Apex Committee’s request to the CBDT “does not compel the receiving authority to act.” Whether the doctors attended as delegates (barred from accepting travel or hotel benefits) or under genuine professional engagements was a factual question for the competent authorities. Sudarshan V. Biradar v. State of Karnataka was distinguished, and interim orders of the Delhi and Gujarat High Courts obtained by doctors were not relied on.
What the Court Actually Held
- An anonymous complaint is no ground to quash the Apex Committee’s order; UCPMP 2024 does not bar the DOP from receiving and verifying such a complaint through a special audit.
- The Ethics Committee’s decision is final only within the association’s mechanism and does not bind the DOP; no appeal or review was needed for the Apex Committee to act.
- The writ petition was dismissed; the Income Tax Department may proceed on its independent assessment, with the company free to raise objections there.
- The ROC notice was not quashed, but the inquiry must strictly follow Section 206(4) of the Companies Act; the company must reply within four weeks.
Why This Judgment Matters
- It is a significant early ruling on the enforcement architecture of UCPMP 2024 and the DOP’s independent power to act.
- It shows that industry self-regulation outcomes do not shield companies from government scrutiny of marketing to doctors.
- It balances enforcement with procedural fairness by requiring the ROC to follow Section 206(4) and treat the Apex Committee order as non-binding.
What Should Advocates Take Away From the Judgment?
For Pharma Companies and Doctors
- Sponsorship of foreign conference travel for delegates is squarely within UCPMP scrutiny.
- A clean chit from the industry Ethics Committee will not end a DOP inquiry.
- Keep records showing genuine professional engagements where doctors are funded.
For Counsel
- Challenge procedure before the ROC under Section 206(4) rather than seeking to quash notices outright.
- Raise factual defences (delegate vs. professional engagement) before the competent authority.
- Note the Court’s reading of Clause 10.7 as an independent DOP channel.
Key Takeaways
- The DOP may act on an anonymous complaint verified through a special audit.
- UCPMP 2024 governed the procedure from May 2024.
- Ethics Committee findings do not bind the DOP.
- Income Tax and ROC proceedings can continue, with ROC bound by Section 206(4).
Frequently Asked Questions
What was AbbVie accused of?
An anonymous complaint alleged it funded trips for 30 healthcare professionals to conferences in Paris and Monaco in 2024 under the guise of conferences; the Apex Committee reprimanded it for unethical marketing practices.
Did the Ethics Committee’s clean chit help the company?
No. The Court held that the decision was final only within the association’s complaint mechanism and did not bind the DOP.
What happens to the tax and ROC proceedings?
They can proceed. The ROC must follow Section 206(4), giving written allegations and a hearing, and the company must reply within four weeks.
Conclusion
The ruling strengthens the Department of Pharmaceuticals’ hand under UCPMP 2024 while making clear that the Apex Committee’s order is not a binding finding for other regulators, who must make their own assessment with due process.
Practical takeaway: Pharma companies should treat UCPMP compliance as a government-enforced obligation, not merely an industry code, and prepare to defend sponsorships on facts before tax and company-law authorities.
Read the full judgment on CourtKutchehry: View judgment →
For more judgments, legal opinions and case analysis, visit courtkutchehry.com